<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="crj70082" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Respir J</journal-id><journal-id journal-id-type="iso-abbrev">Clin Respir J</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1752-699X</journal-id><journal-id journal-id-type="publisher-id">CRJ</journal-id><journal-title-group><journal-title>The Clinical Respiratory Journal</journal-title></journal-title-group><issn pub-type="ppub">1752-6981</issn><issn pub-type="epub">1752-699X</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40396530</article-id><article-id pub-id-type="pmc">PMC12093249</article-id><article-id pub-id-type="doi">10.1111/crj.70082</article-id><article-id pub-id-type="publisher-id">CRJ70082</article-id><article-id pub-id-type="other">CRJ-OA-03-2024-205.R2</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>LncRNA HOXA&#x02010;AS2 Can Predict the Risk of Acute Respiratory Distress Syndrome and 28&#x02010;Day Mortality in Patients With Sepsis</article-title></title-group><contrib-group><contrib id="crj70082-cr-0001" contrib-type="author"><name><surname>Quan</surname><given-names>Youhong</given-names></name><xref rid="crj70082-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="crj70082-cr-0002" contrib-type="author" corresp="yes"><name><surname>Gao</surname><given-names>Song</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-8915-3995</contrib-id><xref rid="crj70082-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>gaosongdr@163.com</email></address></contrib></contrib-group><aff id="crj70082-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Intensive Care Unit</named-content>
<institution>Wuxi Branch of Zhongda Hospital Southeast University</institution>
<city>Wuxi</city>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Song Gao (<email>gaosongdr@163.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><volume>19</volume><issue seq="110">5</issue><issue-id pub-id-type="doi">10.1111/crj.v19.5</issue-id><elocation-id>e70082</elocation-id><history>
<date date-type="rev-recd"><day>29</day><month>4</month><year>2025</year></date>
<date date-type="received"><day>25</day><month>3</month><year>2024</year></date>
<date date-type="accepted"><day>02</day><month>5</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 The Author(s). The Clinical Respiratory Journal published by John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). The Clinical Respiratory Journal published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CRJ-19-e70082.pdf"/><abstract><title>ABSTRACT</title><sec id="crj70082-sec-0001"><title>Objective</title><p>This study aimed to explore the diagnostic and predictive value of lncRNA HOXA&#x02010;AS2 for acute respiratory distress syndrome (ARDS) and 28&#x02010;day mortality in sepsis patients.</p></sec><sec id="crj70082-sec-0002"><title>Methods</title><p>The levels of HOXA&#x02010;AS2 in sepsis and ARDS patients were detected by real&#x02010;time quantitative reverse transcription PCR (RT&#x02010;qPCR). The receiver operating curve (ROC) curve was used to evaluate the diagnostic value of HOXA&#x02010;AS2 for sepsis and ARDS. The K&#x02010;M curve was used to evaluate the effect of HOXA&#x02010;AS2 on the prognosis. Logistic regression analysis and COX regression analysis were used to explore the risk factors influencing ARDS and death. Additionally, an ARDS cell model was constructed to explore the effects of HOXA&#x02010;AS2 on cell viability, inflammation, and endothelial glycocalyx.</p></sec><sec id="crj70082-sec-0003"><title>Results</title><p>HOXA&#x02010;AS2 decreased in sepsis patients who developed ARDS and died. This molecule can not only serve as a diagnostic marker for sepsis but also act as a risk factor to predict the risk of ARDS and death within 28&#x02009;days in patients with sepsis. Sepsis patients with low levels of HOXA&#x02010;AS2 are more prone to ARDS and death. In cells attacked by lipopolysaccharide (LPS), overexpression of HOXA&#x02010;AS2 inhibited apoptosis, inflammation, and the degradation of endothelial glycocalyx.</p></sec><sec id="crj70082-sec-0004"><title>Conclusion</title><p>In sepsis patients, HOXA&#x02010;AS2 has the potential to serve as a predictive marker for ARDS and 28&#x02010;day mortality. This molecule may delay the progression of ARDS by inhibiting inflammation and the degradation of the endothelial glycocalyx.</p></sec></abstract><abstract abstract-type="graphical"><p>LncRNA HOXA&#x02010;AS2 is not only a diagnostic marker for sepsis but also can predict the risk of acute respiratory distress syndrome (ARDS) and 28&#x02010;day mortality in patients with sepsis.<boxed-text position="anchor" content-type="graphic" id="crj70082-blkfxd-0001"><graphic xlink:href="CRJ-19-e70082-g003.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="crj70082-kwd-0001">ARDS</kwd><kwd id="crj70082-kwd-0002">diagnosis</kwd><kwd id="crj70082-kwd-0003">HOXA&#x02010;AS2</kwd><kwd id="crj70082-kwd-0004">prognosis</kwd><kwd id="crj70082-kwd-0005">sepsis</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Wuxi Double Hundred Talents Project Topic</funding-source><award-id>HB2023118</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="4"/><page-count count="10"/><word-count count="5700"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:21.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="crj70082-ntgp-0001"><fn fn-type="funding" id="crj70082-note-0001"><p>
<bold>Funding:</bold> This study was funded by the Wuxi Double Hundred Talents Project Topic (HB2023118).</p></fn></fn-group></notes></front><body id="crj70082-body-0001"><sec id="crj70082-sec-0005"><label>1</label><title>Introduction</title><p>Sepsis is a syndrome characterized by a systemic inflammatory response, which can lead to a dysregulation reaction to bacterial, fungal, viral, and parasitic infections in a patient's body. This can result in multi&#x02010;organ failure and, in severe cases, may be life&#x02010;threatening [<xref rid="crj70082-bib-0001" ref-type="bibr">1</xref>, <xref rid="crj70082-bib-0002" ref-type="bibr">2</xref>]. Sepsis continues to be one of the main contributors to the global mortality [<xref rid="crj70082-bib-0003" ref-type="bibr">3</xref>]. Acute respiratory distress syndrome (ARDS) is an acute inflammatory injury and the most common and severe complication in sepsis [<xref rid="crj70082-bib-0004" ref-type="bibr">4</xref>, <xref rid="crj70082-bib-0005" ref-type="bibr">5</xref>]. Globally, ARDS affects at least seven out of every 100&#x02009;000 people [<xref rid="crj70082-bib-0006" ref-type="bibr">6</xref>]. It is a rapidly progressing disease with a poor prognosis. Despite numerous effective measures taken in recent years to address ARDS, the mortality rate for patients with ARDS remains above 25% [<xref rid="crj70082-bib-0007" ref-type="bibr">7</xref>, <xref rid="crj70082-bib-0008" ref-type="bibr">8</xref>, <xref rid="crj70082-bib-0009" ref-type="bibr">9</xref>]. Therefore, the early identification and diagnosis of patients with sepsis and those at risk of ARDS are critical to improving patient prognosis and reducing mortality.</p><p>LncRNA is a noncoding RNA with a length of over 200 nucleotides [<xref rid="crj70082-bib-0010" ref-type="bibr">10</xref>]. It plays a crucial role in regulating cell activities and determining cell fate, thereby ensuring the normal process of organism reproduction, growth, development, and other life activities [<xref rid="crj70082-bib-0011" ref-type="bibr">11</xref>]. There is increasing evidence that lncRNA is related to the occurrence and development of many major diseases [<xref rid="crj70082-bib-0012" ref-type="bibr">12</xref>]. Consequently, lncRNA is becoming promising disease markers and drug targets, succeeding protein molecules [<xref rid="crj70082-bib-0013" ref-type="bibr">13</xref>]. LncRNA has also been demonstrated to be associated with sepsis and ARDS in sepsis. For instance, the downregulation of LncRNA NEAT1 may improve the inflammatory response and cell cycle progression of sepsis&#x02010;induced ARDS [<xref rid="crj70082-bib-0014" ref-type="bibr">14</xref>]. LncRNA MEG3 is abnormally expressed in ARDS patients and positively correlates with disease severity [<xref rid="crj70082-bib-0015" ref-type="bibr">15</xref>]. HOXA antisense RNA 2 (HOXA&#x02010;AS2) is a lncRNA of length 1048, located between the HOXA3 and HOXA4 genes [<xref rid="crj70082-bib-0016" ref-type="bibr">16</xref>]. Study found that upregulation of HOXA&#x02010;AS2 can reverse acute kidney injury caused by sepsis [<xref rid="crj70082-bib-0017" ref-type="bibr">17</xref>]. HOXA&#x02010;AS2 can alleviate lung inflammation caused by chronic intermittent hypoxia. Overexpression of HOXA&#x02010;AS2 mitigates lung injury in chronic intermittent hypoxia rats by inhibiting apoptosis, improving hypoxemia, and altering the level of inflammatory factors [<xref rid="crj70082-bib-0018" ref-type="bibr">18</xref>]. HOXA&#x02010;AS2 is downregulated in patients with chronic obstructive pulmonary disease (COPD) and is associated with endothelial cell proliferation [<xref rid="crj70082-bib-0019" ref-type="bibr">19</xref>]. HOXA&#x02010;AS2 has also been shown to inhibit endothelial cell inflammation [<xref rid="crj70082-bib-0020" ref-type="bibr">20</xref>]. Pulmonary capillary endothelial cells are not just the target cells of inflammation in ARDS but also important effector cells [<xref rid="crj70082-bib-0021" ref-type="bibr">21</xref>]. The breakdown of pulmonary capillary endothelial cell barrier plays a pivotal role in the occurrence and development of ARDS [<xref rid="crj70082-bib-0022" ref-type="bibr">22</xref>]. However, whether HOXA&#x02010;AS2 is associated with the development of ARDS in sepsis remains unclear. Whether HOXA&#x02010;AS2 is a valuable predictive biomarker of ARDS in sepsis requires further investigation.</p><p>Based on previous studies, we hypothesize that HOXA&#x02010;AS2 plays a role in the occurrence and development of sepsis and sepsis&#x02010;related ARDS. This study aims to explore the mechanism of HOXA&#x02010;AS2 involved in sepsis&#x02010;related ARDS and the predictive value of this molecule for ARDS and 28&#x02010;day mortality. This may provide valuable biomarkers for the diagnosis, treatment, and prognosis of sepsis and ARDS.</p></sec><sec sec-type="materials-and-methods" id="crj70082-sec-0006"><label>2</label><title>Materials and Methods</title><sec id="crj70082-sec-0007"><label>2.1</label><title>Participants</title><p>From July 2019 to August 2020, 122 patients with sepsis were enrolled in Wuxi Branch of Zhongda Hospital Southeast University hospital. The enrollment criteria were as follows: (a) diagnosed as sepsis patients [<xref rid="crj70082-bib-0023" ref-type="bibr">23</xref>]; (b) age over 18&#x02009;years; (c) admission to hospital within 24&#x02009;h; (d) no immunosuppressive therapy in the last 3&#x02009;months; (e) no complications from other fatal diseases; and (f) no cancer or malignant tumors. Patients with sepsis did not meet the diagnostic criteria for ARDS before enrollment. Additionally, we recruited 101 healthy volunteers without sepsis to serve as a control group. Both groups were matched for age and gender. The criteria for the control group included (a) the physical examination result is normal; (b) no history of cancer or sepsis; and (c) no immunosuppressive drugs have been used recently.</p><p>Our study received approval from the Institutional Review Board of Zhongda Hospital Southeast University's Wuxi Branch. All subjects also provided written informed consent.</p></sec><sec id="crj70082-sec-0008"><label>2.2</label><title>Specimen Collection</title><p>Upon admission, we recorded the patient's baseline clinical features in detail. We diagnosed the severity of sepsis in the patient using the SOFA score and APACHE II score within 24&#x02009;h. We collected blood samples from both the control group and sepsis patients on their respective enrollment and admission days. We stored the separated serum at &#x02212;80&#x000b0;C.</p></sec><sec id="crj70082-sec-0009"><label>2.3</label><title>RNA Extraction and Real&#x02010;Time Quantitative Reverse Transcription PCR (RT&#x02010;qPCR)</title><p>First, we isolated the serum total RNA using the TRIZOL regent. We then determined the RNA purity and concentration using the NanoDrop 1000 spectrophotometer. Second, we synthesized cDNA from 2&#x02009;&#x003bc;g of RNA. Finally, we performed amplification reactions after mixing cDNA, primers, RNase Free H<sub>2</sub>O, and SYBR Green Quantitative RT&#x02010;qPCR Kit reagent well. GAPDH is the reference gene. The relative expression of HOXA&#x02010;AS2 was calculated by 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method.</p></sec><sec id="crj70082-sec-0010"><label>2.4</label><title>ARDS Assessment</title><p>After admission, patients with sepsis were closely monitored. ARDS was diagnosed using the Berlin definition&#x000a0;[<xref rid="crj70082-bib-0024" ref-type="bibr">24</xref>], which includes (a) onset within 7&#x02009;days of clinical injury; (b) decreased translucency in both lungs that cannot be fully explained by lobar atelectasis, pleural effusion, or nodules; (c) edema, respiratory failure (not fully explained by cardiac failure or fluid overload); (d) oxygenation (partial pressure of arterial oxygen/fraction of inspired oxygen (PaO<sub>2</sub>/FIO<sub>2</sub>) &#x02264;&#x02009;300&#x02009;mmHg with positive end&#x02010;expiratory pressure (PEEP) &#x02265;&#x02009;5&#x02010;cm H<sub>2</sub>O).</p></sec><sec id="crj70082-sec-0011"><label>2.5</label><title>Cell Culture, Treatment, and Transfected</title><p>Human pulmonary microvascular endothelial cells (HPMECs) were purchased from Pricella Biotech (Wuhan, China). The cells were cultured in a complete culture medium (Pricella, Wuhan, China), under conditions of 37&#x000b0;C and 5% CO2. To construct an in&#x000a0;vitro ARDS cell model, we treated HPMECs with 100ng/mL lipopolysaccharide (LPS) for 24&#x02009;h.</p><p>Overexpressing plasmids of HOXA&#x02010;AS2 (oe&#x02010;HOXA&#x02010;AS2) and the negative control (oe&#x02010;NC) were synthesized by GenePharma (Shanghai, China). When HPMECs are in the logarithmic growth phase, we transfected the oe&#x02010;HOXA&#x02010;AS2 and oe&#x02010;NC plasmids into HPMECs using Lipo6000 (Beyotime, Shanghai, China).</p></sec><sec id="crj70082-sec-0012"><label>2.6</label><title>Cell Viability Assay</title><p>We inoculated HPMEC cells into 96&#x02010;well plates (5&#x02009;&#x000d7;&#x02009;10<sup>3</sup> cells per well). After incubation, 10&#x02010;&#x003bc;L CCK&#x02010;8 solution was added to each well. After 2&#x02009;h of incubation, we measured the absorbance at 450&#x02009;nm using a microplate reader.</p></sec><sec id="crj70082-sec-0013"><label>2.7</label><title>Cell Apoptosis Assay</title><p>The Annexin V&#x02010;APC/Cyannine7/PI Apoptosis Kit (Elabscience, Wuhan, China) was used for apoptosis detection. HPMECs were first cleaned with PBS buffer. After centrifugation, the supernatant was discarded, and the cells were resuspended in 500&#x02009;&#x003bc;L of 1&#x02009;&#x000d7;&#x02009;Annexin V Binding Buffer. Subsequently, 5&#x02009;&#x003bc;L of Annexin V&#x02010;APC/Cyannine7 Regent and PI Regent were added to the suspension. The cell samples were then incubated at room temperature in the dark for 20&#x02009;min. Following the incubation, apoptotic cells were detected using flow cytometry.</p></sec><sec id="crj70082-sec-0014"><label>2.8</label><title>Enzyme&#x02010;Linked Immunosorbent Assay (ELISA)</title><p>The concentrations of IL&#x02010;6, TNF&#x02010;&#x003b1;, IL&#x02010;1&#x003b2;, and IL&#x02010;8 were measured using commercial Human IL&#x02010;6, TNF&#x02010;&#x003b1;, IL&#x02010;1&#x003b2;, and IL&#x02010;8 ELISA Kits (Solarbio, Beijing, China). We strictly adhered to the instructions provided with the kit.</p></sec><sec id="crj70082-sec-0015"><label>2.9</label><title>Statistical Analysis</title><p>SPSS 23.0 software (IBM) and GraphPad Prism 9.0 software were used for statistical analysis and charting. The data were presented as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD), mean with interquartile range (IQR), and number (percentage). The student's <italic toggle="yes">t</italic>&#x02010;test and the Mann&#x02013;Whitney <italic toggle="yes">U</italic> test were used for comparison of differences among variables, and the Spearman's rank correlation test was used for correlation analysis. The diagnostic value of HOXA&#x02010;AS2 in sepsis and ARDS was analyzed using receiver operating characteristic (ROC) curve. The Kaplan&#x02013;Meier curve was used to describe the relationship between HOXA&#x02010;AS2 levels and cumulative mortality in sepsis patients. The logistic regression analysis and COX regression analysis were used to analyze the risk factors affecting ARDS and 28&#x02010;day mortality. <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="crj70082-sec-0016"><label>3</label><title>Results</title><sec id="crj70082-sec-0017"><label>3.1</label><title>Clinical Characteristics of Sepsis Patients</title><p>In this study, 122 sepsis patients were enrolled. The average age was 54.78&#x02009;&#x000b1;&#x02009;10.06&#x02009;years, with 58.20% being male. COPD was found in 20.49% of sepsis patients, cardiomyopathy in 39.34%, chronic renal failure in 16.39%, and cirrhosis in 21.31%. In terms of infection types, 45 (36.89%) of the patients had abdominal infections, 25 (20.49%) had respiratory infections, 23 (18.85%) had skin and soft tissue infections, 14 (11.48%) had bloodstream infections, 7 (5.74%) had central nervous system infections, and 8 (6.56%) had other types of infections. Additional details are listed in Table&#x000a0;<xref rid="crj70082-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="crj70082-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Comparison of basic clinical information of patients with sepsis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameters</th><th align="center" valign="bottom" rowspan="1" colspan="1">Sepsis patients (<italic toggle="no">n</italic>&#x02009;=&#x02009;122)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Control (<italic toggle="no">n</italic>&#x02009;=&#x02009;101)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (y), mean&#x02009;&#x000b1;&#x02009;SD</td><td align="center" valign="top" rowspan="1" colspan="1">54.78&#x02009;&#x000b1;&#x02009;10.06</td><td align="center" valign="top" rowspan="1" colspan="1">54.69&#x02009;&#x000b1;&#x02009;5.67</td><td align="center" valign="top" rowspan="1" colspan="1">0.939</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male, no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1">71 (58.20)</td><td align="center" valign="top" rowspan="1" colspan="1">51 (50.50)</td><td align="center" valign="top" rowspan="1" colspan="1">0.225</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), mean&#x02009;&#x000b1;&#x02009;SD</td><td align="center" valign="top" rowspan="1" colspan="1">22.63&#x02009;&#x000b1;&#x02009;3.88</td><td align="center" valign="top" rowspan="1" colspan="1">23.14&#x02009;&#x000b1;&#x02009;2.82</td><td align="center" valign="top" rowspan="1" colspan="1">0.274</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoke, no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1">47 (38.52)</td><td align="center" valign="top" rowspan="1" colspan="1">42 (41.58)</td><td align="center" valign="top" rowspan="1" colspan="1">0.681</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Complications, no. (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">COPD</td><td align="center" valign="top" rowspan="1" colspan="1">25 (20.49)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cardiomyopathy</td><td align="center" valign="top" rowspan="1" colspan="1">48 (39.34)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic kidney failure</td><td align="center" valign="top" rowspan="1" colspan="1">20 (16.39)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cirrhosis</td><td align="center" valign="top" rowspan="1" colspan="1">26 (21.31)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Primary infection site, no. (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Abdominal infection</td><td align="center" valign="top" rowspan="1" colspan="1">45 (36.89)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Respiratory infection</td><td align="center" valign="top" rowspan="1" colspan="1">25 (20.49)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Skin and soft tissue infection</td><td align="center" valign="top" rowspan="1" colspan="1">23 (18.85)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bloodstream infection</td><td align="center" valign="top" rowspan="1" colspan="1">14 (11.48)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CNS infection</td><td align="center" valign="top" rowspan="1" colspan="1">7 (5.74)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other infection</td><td align="center" valign="top" rowspan="1" colspan="1">8 (6.56)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Primary organism,</bold> no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">G<sup>&#x02212;</sup> bacteria</td><td align="center" valign="top" rowspan="1" colspan="1">65 (53.28)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">G<sup>+</sup> bacteria</td><td align="center" valign="top" rowspan="1" colspan="1">23 (18.85)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anaerobe</td><td align="center" valign="top" rowspan="1" colspan="1">14 (11.48)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fungus</td><td align="center" valign="top" rowspan="1" colspan="1">8 (6.56)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mycoplasmas</td><td align="center" valign="top" rowspan="1" colspan="1">3 (2.46)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total culture negative</td><td align="center" valign="top" rowspan="1" colspan="1">19 (15.57)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Biochemical indexes, median (IQR)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scr (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">1.89 (1.32&#x02013;2.48)</td><td align="center" valign="top" rowspan="1" colspan="1">0.99 (0.88, 1.09)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Albumin, (g/L)</td><td align="center" valign="top" rowspan="1" colspan="1">23.29 (23.74&#x02013;30.44)</td><td align="center" valign="top" rowspan="1" colspan="1">41.33 (38.79, 44.32)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WBC (&#x000d7;10<sup>9</sup>/L)</td><td align="center" valign="top" rowspan="1" colspan="1">21.25 (14.86&#x02013;25.61)</td><td align="center" valign="top" rowspan="1" colspan="1">7.27 (6.44, 8.00)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP (mg/L)</td><td align="center" valign="top" rowspan="1" colspan="1">72.21 (44.03&#x02013;147.07)</td><td align="center" valign="top" rowspan="1" colspan="1">6.11 (4.73, 7.62)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Disease severity, median (IQR)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APAHCE II score</td><td align="center" valign="top" rowspan="1" colspan="1">15.5 (12.00&#x02013;18.00)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SOFA score</td><td align="center" valign="top" rowspan="1" colspan="1">7.5 (5.0&#x02013;10.0)</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table><table-wrap-foot id="crj70082-ntgp-0002"><fn id="crj70082-note-0002"><p>Abbreviations: APACHE, acute physiology and chronic health evaluation; BMI, body mass index; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CRP, C&#x02010;reactive protein; Scr, serum creatinine; SOFA, sequential organ failure assessment; WBC, white blood cells.</p></fn></table-wrap-foot></table-wrap></sec><sec id="crj70082-sec-0018"><label>3.2</label><title>HOXA&#x02010;AS2 Distinguishes Sepsis Patients From Controls</title><p>Compared to controls, HOXA&#x02010;AS2 levels were significantly lower in sepsis patients (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Figure&#x000a0;<xref rid="crj70082-fig-0001" ref-type="fig">1A</xref>). HOXA&#x02010;AS2 levels had a negatively correlation with the APACHE II score (<italic toggle="yes">r</italic>&#x02009;=&#x02009;&#x02212;0.778, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, Figure&#x000a0;<xref rid="crj70082-fig-0001" ref-type="fig">1B</xref>). Similarly, there was a negative correlation between HOXA&#x02010;AS2 and the SOFA score (<italic toggle="yes">r</italic>&#x02009;=&#x02009;&#x02212;0.758, <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, Figure&#x000a0;<xref rid="crj70082-fig-0001" ref-type="fig">1C</xref>). Furthermore, HOXA&#x02010;AS2 could differentiate sepsis patients from controls (AUC&#x02009;=&#x02009;0.865, sensitivity&#x02009;=&#x02009;74.59%, specificity&#x02009;=&#x02009;86.14%, Figure&#x000a0;<xref rid="crj70082-fig-0001" ref-type="fig">1D</xref>).</p><fig position="float" fig-type="FIGURE" id="crj70082-fig-0001"><label>FIGURE 1</label><caption><p>HOXA&#x02010;AS2 is a diagnostic marker for sepsis. (A) The level of HOXA&#x02010;AS2 was determined by RT&#x02010;qPCR. (B&#x02013;C)<styled-content style="fixed-case" toggle="no">
<italic toggle="no">. APACHE</italic>
</styled-content> II score and SOFA score were negatively correlated with HOXA&#x02010;AS2. (D) The performance of HOXA&#x02010;AS2 in distinguishing sepsis patients from healthy controls was analyzed by receiver operating characteristic (ROC) curve. ****<italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="CRJ-19-e70082-g004" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="crj70082-sec-0019"><label>3.3</label><title>Clinical Characteristics of ARDS Sepsis Patients and Non&#x02010;ARDS Sepsis Patients</title><p>During the 28&#x02010;day follow&#x02010;up, 32 sepsis patients developed ARDS. Compared to sepsis patients without ARDS, sepsis with ARDS had higher smoking rates (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.022). The proportion of patients with COPD (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.023) and respiratory infections (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001) was also higher in the ARDS group (Table&#x000a0;<xref rid="crj70082-tbl-0002" ref-type="table">2</xref>). Additionally, the CRP (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.022), SOFA score (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.000), and APACHE II score (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.003) were significantly elevated in sepsis patients with ARDS (Table&#x000a0;<xref rid="crj70082-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="crj70082-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Comparison of basic clinical information of patients with non&#x02010;ARSD sepsis and ARDS sepsis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameters</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non&#x02010;ARDS sepsis patients (<italic toggle="no">n</italic>&#x02009;=&#x02009;90)</th><th align="center" valign="bottom" rowspan="1" colspan="1">ARDS sepsis patients (<italic toggle="no">n</italic>&#x02009;=&#x02009;32)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (y), mean&#x02009;&#x000b1;&#x02009;SD</td><td align="center" valign="top" rowspan="1" colspan="1">55.69&#x02009;&#x000b1;&#x02009;8.99</td><td align="center" valign="top" rowspan="1" colspan="1">52.22&#x02009;&#x000b1;&#x02009;12.41</td><td align="center" valign="top" rowspan="1" colspan="1">0.094</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male, no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1">53 (58.89)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (56.25)</td><td align="center" valign="top" rowspan="1" colspan="1">0.795</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), mean&#x02009;&#x000b1;&#x02009;SD</td><td align="center" valign="top" rowspan="1" colspan="1">22.34&#x02009;&#x000b1;&#x02009;3.97</td><td align="center" valign="top" rowspan="1" colspan="1">23.46&#x02009;&#x000b1;&#x02009;3.56</td><td align="center" valign="top" rowspan="1" colspan="1">0.161</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoke, no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (37.78)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (50.00)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.022</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Complications, no. (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">COPD</td><td align="center" valign="top" rowspan="1" colspan="1">14 (15.56)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (34.38)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.023</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cardiomyopathy</td><td align="center" valign="top" rowspan="1" colspan="1">35 (38.89)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (40.63)</td><td align="center" valign="top" rowspan="1" colspan="1">0.863</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic kidney failure</td><td align="center" valign="top" rowspan="1" colspan="1">13 (14.44)</td><td align="center" valign="top" rowspan="1" colspan="1">77 (21.88)</td><td align="center" valign="top" rowspan="1" colspan="1">0.329</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cirrhosis</td><td align="center" valign="top" rowspan="1" colspan="1">20 (22.22)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (18.75)</td><td align="center" valign="top" rowspan="1" colspan="1">0.680</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Primary infection site, no. (%)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Abdominal infection</td><td align="center" valign="top" rowspan="1" colspan="1">38 (42.22)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (21.88)</td><td align="center" valign="top" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Respiratory infection</td><td align="center" valign="top" rowspan="1" colspan="1">11 (12.22)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (43.75)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Skin and soft tissue infection</td><td align="center" valign="top" rowspan="1" colspan="1">17 (18.89)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (18.75)</td><td align="center" valign="top" rowspan="1" colspan="1">0.986</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bloodstream infection</td><td align="center" valign="top" rowspan="1" colspan="1">12 (13.33)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.25)</td><td align="center" valign="top" rowspan="1" colspan="1">0.352</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CNS infection</td><td align="center" valign="top" rowspan="1" colspan="1">5 (5.56)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.25)</td><td align="center" valign="top" rowspan="1" colspan="1">0.885</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other infection</td><td align="center" valign="top" rowspan="1" colspan="1">7 (7.78)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.679</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Primary organism,</bold> no. (%)</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">G<sup>&#x02212;</sup> bacteria</td><td align="center" valign="top" rowspan="1" colspan="1">47 (52.22)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (56.25)</td><td align="center" valign="top" rowspan="1" colspan="1">0.837</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">G<sup>+</sup> bacteria</td><td align="center" valign="top" rowspan="1" colspan="1">17 (18.89)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (18.75)</td><td align="center" valign="top" rowspan="1" colspan="1">0.986</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anaerobe</td><td align="center" valign="top" rowspan="1" colspan="1">9 (10.00)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (15.63)</td><td align="center" valign="top" rowspan="1" colspan="1">0.391</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fungus</td><td align="center" valign="top" rowspan="1" colspan="1">6 (6.67)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.25)</td><td align="center" valign="top" rowspan="1" colspan="1">0.935</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mycoplasmas</td><td align="center" valign="top" rowspan="1" colspan="1">2 (2.22)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.777</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total culture negative</td><td align="center" valign="top" rowspan="1" colspan="1">13 (14.44)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (18.75)</td><td align="center" valign="top" rowspan="1" colspan="1">0.564</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Biochemical indexes, median (IQR)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scr (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">1.89 (1.32&#x02013;2.44)</td><td align="center" valign="top" rowspan="1" colspan="1">1.93 (1.32&#x02013;2.68)</td><td align="center" valign="top" rowspan="1" colspan="1">0.896</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Albumin, (g/L)</td><td align="center" valign="top" rowspan="1" colspan="1">27.29 (24.01&#x02013;31.10)</td><td align="center" valign="top" rowspan="1" colspan="1">26.70 (22.27&#x02013;30.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.511</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WBC (&#x000d7;10<sup>9</sup>/L)</td><td align="center" valign="top" rowspan="1" colspan="1">19.65 (14.35&#x02013;25.40)</td><td align="center" valign="top" rowspan="1" colspan="1">23.52 (19.83&#x02013;26.52)</td><td align="center" valign="top" rowspan="1" colspan="1">0.076</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP (mg/L)</td><td align="center" valign="top" rowspan="1" colspan="1">67.72 (43.05&#x02013;126.79)</td><td align="center" valign="top" rowspan="1" colspan="1">131.48 (49.71&#x02013;186.18)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.022</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Disease severity, median (IQR)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APAHCE II score</td><td align="center" valign="top" rowspan="1" colspan="1">15.00 (11.00&#x02013;17.00)</td><td align="center" valign="top" rowspan="1" colspan="1">17.00 (15.00&#x02013;19.00)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.003</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SOFA score</td><td align="center" valign="top" rowspan="1" colspan="1">6.00 (4.00&#x02013;8.25)</td><td align="center" valign="top" rowspan="1" colspan="1">13.00 (8.00&#x02013;15.00)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.000</bold>
</td></tr></tbody></table><table-wrap-foot id="crj70082-ntgp-0003"><fn id="crj70082-note-0003"><p>Abbreviations: APACHE, acute physiology and chronic health evaluation; BMI, body mass index; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CRP, C&#x02010;reactive protein; Scr, serum creatinine; SOFA, sequential organ failure assessment; WBC, white blood cells.</p></fn></table-wrap-foot></table-wrap></sec><sec id="crj70082-sec-0020"><label>3.4</label><title>HOXA&#x02010;AS2 Predicts ARDS Risk in Sepsis Patients</title><p>Compared to non&#x02010;ARDS sepsis patients, HOXA&#x02010;AS2 levels were significantly decreased in ARDS sepsis patients (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Figure&#x000a0;<xref rid="crj70082-fig-0002" ref-type="fig">2A</xref>). HOXA&#x02010;AS2 can differentiate ARDS sepsis patients from non&#x02010;ARDS sepsis patients (AUC&#x02009;=&#x02009;0.843, sensitivity&#x02009;=&#x02009;78.13%, specificity&#x02009;=&#x02009;74.44%. Figure&#x000a0;<xref rid="crj70082-fig-0002" ref-type="fig">2B</xref>).</p><fig position="float" fig-type="FIGURE" id="crj70082-fig-0002"><label>FIGURE 2</label><caption><p>In patients with sepsis, HOXA&#x02010;AS2 can be used as a diagnostic marker for acute respiratory distress syndrome (ARDS). (A) The level of HOXA&#x02010;AS2 was determined by RT&#x02010;qPCR. (B) The performance of HOXA&#x02010;AS2 in distinguishing ARDS patients from non&#x02010;ARDS patients was analyzed by receiver operating characteristic (ROC) curve. ****<italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="CRJ-19-e70082-g001" position="anchor" id="jats-graphic-5"/></fig><p>As is shown in Table&#x000a0;<xref rid="crj70082-tbl-0003" ref-type="table">3</xref>, we used logistic regression analysis to examine the clinical characteristics and the level of HOXA&#x02010;AS2 in ARDS sepsis patients and non&#x02010;ARDS sepsis patients, in order to analyze risk factors for the development of ARDS. The results indicated that HOXA&#x02010;AS2 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.002), COPD (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.029), primary infection site (respiratory vs. others) (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.005), and SOFA score (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.004) were independent risk factors for ARDS.</p><table-wrap position="float" id="crj70082-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Analysis of risk factors of ARDS in patients with sepsis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Parameters</th><th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Univariate logistic regression</th><th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Multivariate logistic regression</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">OR</th><th align="center" valign="bottom" rowspan="1" colspan="1">95%CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR</th><th align="center" valign="bottom" rowspan="1" colspan="1">95%CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">0.749</td><td align="center" valign="top" rowspan="1" colspan="1">0.317&#x02013;1.770</td><td align="center" valign="top" rowspan="1" colspan="1">0.510</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="center" valign="top" rowspan="1" colspan="1">0.898</td><td align="center" valign="top" rowspan="1" colspan="1">0.397&#x02013;2.028</td><td align="center" valign="top" rowspan="1" colspan="1">0.795</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">0.807</td><td align="center" valign="top" rowspan="1" colspan="1">0.360&#x02013;1.811</td><td align="center" valign="top" rowspan="1" colspan="1">0.604</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoke</td><td align="center" valign="top" rowspan="1" colspan="1">2.571</td><td align="center" valign="top" rowspan="1" colspan="1">1.127&#x02013;5.865</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.025</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.434</td><td align="center" valign="top" rowspan="1" colspan="1">0.154&#x02013;1.222</td><td align="center" valign="top" rowspan="1" colspan="1">0.114</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">COPD</td><td align="center" valign="top" rowspan="1" colspan="1">2.844</td><td align="center" valign="top" rowspan="1" colspan="1">1.127&#x02013;7.177</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.027</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.227</td><td align="center" valign="top" rowspan="1" colspan="1">0.060&#x02013;0.860</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.029</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cardiomyopathy</td><td align="center" valign="top" rowspan="1" colspan="1">1.075</td><td align="center" valign="top" rowspan="1" colspan="1">0.472&#x02013;2.448</td><td align="center" valign="top" rowspan="1" colspan="1">0.863</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic kidney failure</td><td align="center" valign="top" rowspan="1" colspan="1">1.658</td><td align="center" valign="top" rowspan="1" colspan="1">0.596&#x02013;4.616</td><td align="center" valign="top" rowspan="1" colspan="1">0.333</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cirrhosis</td><td align="center" valign="top" rowspan="1" colspan="1">1.238</td><td align="center" valign="top" rowspan="1" colspan="1">0.448&#x02013;3.424</td><td align="center" valign="top" rowspan="1" colspan="1">0.681</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary infection site (respiratory vs. others)</td><td align="center" valign="top" rowspan="1" colspan="1">3.889</td><td align="center" valign="top" rowspan="1" colspan="1">1.594&#x02013;9.486</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.177</td><td align="center" valign="top" rowspan="1" colspan="1">0.052&#x02013;0.600</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.005</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary infection organism</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">G<sup>&#x02212;</sup> vs. others</td><td align="center" valign="top" rowspan="1" colspan="1">1.176</td><td align="center" valign="top" rowspan="1" colspan="1">0.522&#x02013;2.649</td><td align="center" valign="top" rowspan="1" colspan="1">0.695</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">G<sup>+</sup> vs. others</td><td align="center" valign="top" rowspan="1" colspan="1">1.009</td><td align="center" valign="top" rowspan="1" colspan="1">0.359&#x02013;2.834</td><td align="center" valign="top" rowspan="1" colspan="1">0.986</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anaerobes/fungi/mycoplasmas vs. others</td><td align="center" valign="top" rowspan="1" colspan="1">1.431</td><td align="center" valign="top" rowspan="1" colspan="1">0.549&#x02013;3.733</td><td align="center" valign="top" rowspan="1" colspan="1">0.463</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scr</td><td align="center" valign="top" rowspan="1" colspan="1">1.344</td><td align="center" valign="top" rowspan="1" colspan="1">0.597&#x02013;3.026</td><td align="center" valign="top" rowspan="1" colspan="1">0.475</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Albumin</td><td align="center" valign="top" rowspan="1" colspan="1">1.286</td><td align="center" valign="top" rowspan="1" colspan="1">0.571&#x02013;2.895</td><td align="center" valign="top" rowspan="1" colspan="1">0.544</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WBC</td><td align="center" valign="top" rowspan="1" colspan="1">1.996</td><td align="center" valign="top" rowspan="1" colspan="1">0.863&#x02013;4.616</td><td align="center" valign="top" rowspan="1" colspan="1">0.106</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP</td><td align="center" valign="top" rowspan="1" colspan="1">2.387</td><td align="center" valign="top" rowspan="1" colspan="1">1.041&#x02013;5.474</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.040</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.548</td><td align="center" valign="top" rowspan="1" colspan="1">0.190&#x02013;1.578</td><td align="center" valign="top" rowspan="1" colspan="1">0.265</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APAHCE II score</td><td align="center" valign="top" rowspan="1" colspan="1">2.386</td><td align="center" valign="top" rowspan="1" colspan="1">1.031&#x02013;5.526</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.042</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.394</td><td align="center" valign="top" rowspan="1" colspan="1">0.105&#x02013;1.478</td><td align="center" valign="top" rowspan="1" colspan="1">0.167</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SOFA score</td><td align="center" valign="top" rowspan="1" colspan="1">4.297</td><td align="center" valign="top" rowspan="1" colspan="1">1.741&#x02013;10.608</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.004</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.152</td><td align="center" valign="top" rowspan="1" colspan="1">0.042&#x02013;0.554</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.004</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HOXA&#x02010;AS2</td><td align="center" valign="top" rowspan="1" colspan="1">8.100</td><td align="center" valign="top" rowspan="1" colspan="1">2.854&#x02013;22.992</td><td align="center" valign="top" rowspan="1" colspan="1">0.000</td><td align="center" valign="top" rowspan="1" colspan="1">0.100</td><td align="center" valign="top" rowspan="1" colspan="1">0.023&#x02013;0.426</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr></tbody></table><table-wrap-foot id="crj70082-ntgp-0004"><fn id="crj70082-note-0004"><p>Abbreviations: APACHE, acute physiology and chronic health evaluation; BMI, body mass index; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CRP, C&#x02010;reactive protein; Scr, serum creatinine; SOFA, sequential organ failure assessment; WBC, white blood cells.</p></fn></table-wrap-foot></table-wrap></sec><sec id="crj70082-sec-0021"><label>3.5</label><title>lncRNA HOXA&#x02010;AS2 Can Predict 28&#x02010;Day Mortality in Sepsis Patients</title><p>During the 28&#x02010;day follow&#x02010;up period, there were 30 (24.59%) deaths and 92 (75.41%) survivors. Compared to survivors, HOXA&#x02010;AS2 levels were significantly decreased in those who died within 28&#x02009;day (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Figure&#x000a0;<xref rid="crj70082-fig-0003" ref-type="fig">3A</xref>). The ROC curve suggests that the relative expression level of HOXA&#x02010;AS2 can predict mortality risk in sepsis patients (AUC&#x02009;=&#x02009;0.911, sensitivity&#x02009;=&#x02009;83.33%, specificity&#x02009;=&#x02009;85.87%. Figure&#x000a0;<xref rid="crj70082-fig-0003" ref-type="fig">3B</xref>). Moreover, sepsis patients with lower HOXA&#x02010;AS2 expression have a higher mortality rate (log&#x02010;rank <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.027, Figure&#x000a0;<xref rid="crj70082-fig-0003" ref-type="fig">3C</xref>). Multivariate COX regression analysis shows that HOXA&#x02010;AS2 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.005, HR&#x02009;=&#x02009;5.380), SOFA score (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.040, HR&#x02009;=&#x02009;3.960) and APACHE II score (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.013, HR&#x02009;=&#x02009;5.380) are independent risk factors for death in sepsis patients (Table&#x000a0;<xref rid="crj70082-tbl-0004" ref-type="table">4</xref>).</p><fig position="float" fig-type="FIGURE" id="crj70082-fig-0003"><label>FIGURE 3</label><caption><p>Serum HOXA&#x02010;AS2 significantly predicts 28&#x02010;day mortality in sepsis patients. (A) The level of HOXA&#x02010;AS2 was determined by RT&#x02010;qPCR. (B) The predictive value of HOXA&#x02010;AS2 in 28&#x02010;day mortality risk was analyzed by receiver operating characteristic (ROC) curve. (C) The relationship between HOXA&#x02010;AS2 levels and the survival rate of patients with sepsis was analyzed by the Kaplan&#x02013;Meier curve. ****<italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></caption><graphic xlink:href="CRJ-19-e70082-g002" position="anchor" id="jats-graphic-7"/></fig><table-wrap position="float" id="crj70082-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Cox regression analysis of independent risk factors for 28&#x02010;day mortality in patients with sepsis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th rowspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" colspan="1">Parameters</th><th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Univariate Cox</th><th align="center" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Multivariate Cox</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">HR</th><th align="center" valign="bottom" rowspan="1" colspan="1">95%CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">HR</th><th align="center" valign="bottom" rowspan="1" colspan="1">95%CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="no">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Age</td><td align="center" valign="top" rowspan="1" colspan="1">1.002</td><td align="center" valign="top" rowspan="1" colspan="1">0.483&#x02013;2.079</td><td align="center" valign="top" rowspan="1" colspan="1">0.996</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender</td><td align="center" valign="top" rowspan="1" colspan="1">0.809</td><td align="center" valign="top" rowspan="1" colspan="1">0.382&#x02013;1.715</td><td align="center" valign="top" rowspan="1" colspan="1">0.580</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">0.956</td><td align="center" valign="top" rowspan="1" colspan="1">0.461&#x02013;1.981</td><td align="center" valign="top" rowspan="1" colspan="1">0.903</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoke</td><td align="center" valign="top" rowspan="1" colspan="1">2.589</td><td align="center" valign="top" rowspan="1" colspan="1">1.136&#x02013;5.901</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.024</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.783</td><td align="center" valign="top" rowspan="1" colspan="1">0.669&#x02013;4.752</td><td align="center" valign="top" rowspan="1" colspan="1">0.247</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">COPD</td><td align="center" valign="top" rowspan="1" colspan="1">2.313</td><td align="center" valign="top" rowspan="1" colspan="1">1.110&#x02013;4.819</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.025</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.002</td><td align="center" valign="top" rowspan="1" colspan="1">0.333&#x02013;3.016</td><td align="center" valign="top" rowspan="1" colspan="1">0.997</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cardiomyopathy</td><td align="center" valign="top" rowspan="1" colspan="1">0.287</td><td align="center" valign="top" rowspan="1" colspan="1">0.305&#x02013;1.420</td><td align="center" valign="top" rowspan="1" colspan="1">0.658</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chronic kidney failure</td><td align="center" valign="top" rowspan="1" colspan="1">0.373</td><td align="center" valign="top" rowspan="1" colspan="1">0.088&#x02013;1.578</td><td align="center" valign="top" rowspan="1" colspan="1">0.180</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cirrhosis</td><td align="center" valign="top" rowspan="1" colspan="1">0.811</td><td align="center" valign="top" rowspan="1" colspan="1">0.324&#x02013;2.027</td><td align="center" valign="top" rowspan="1" colspan="1">0.654</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary infection site (respiratory vs. others)</td><td align="center" valign="top" rowspan="1" colspan="1">2.209</td><td align="center" valign="top" rowspan="1" colspan="1">1.056&#x02013;4.623</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.035</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.996</td><td align="center" valign="top" rowspan="1" colspan="1">0.856&#x02013;4.338</td><td align="center" valign="top" rowspan="1" colspan="1">0.113</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primary infection organism</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">G<sup>&#x02212;</sup> vs. others</td><td align="center" valign="top" rowspan="1" colspan="1">0.899</td><td align="center" valign="top" rowspan="1" colspan="1">0.431&#x02013;1.877</td><td align="center" valign="top" rowspan="1" colspan="1">0.777</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">G<sup>+</sup> vs. others</td><td align="center" valign="top" rowspan="1" colspan="1">0.743</td><td align="center" valign="top" rowspan="1" colspan="1">0.298&#x02013;1.850</td><td align="center" valign="top" rowspan="1" colspan="1">0.523</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anaerobes/fungi/mycoplasmas vs. others</td><td align="center" valign="top" rowspan="1" colspan="1">0.799</td><td align="center" valign="top" rowspan="1" colspan="1">0.324&#x02013;1.967</td><td align="center" valign="top" rowspan="1" colspan="1">0.625</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Scr</td><td align="center" valign="top" rowspan="1" colspan="1">2.303</td><td align="center" valign="top" rowspan="1" colspan="1">1.047&#x02013;5.065</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.038</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.927</td><td align="center" valign="top" rowspan="1" colspan="1">0.856&#x02013;4.338</td><td align="center" valign="top" rowspan="1" colspan="1">0.113</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Albumin</td><td align="center" valign="top" rowspan="1" colspan="1">2.039</td><td align="center" valign="top" rowspan="1" colspan="1">0.902&#x02013;4.608</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.087</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.090</td><td align="center" valign="top" rowspan="1" colspan="1">0.440&#x02013;5.697</td><td align="center" valign="top" rowspan="1" colspan="1">0.852</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WBC</td><td align="center" valign="top" rowspan="1" colspan="1">2.323</td><td align="center" valign="top" rowspan="1" colspan="1">0.942&#x02013;5.725</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.067</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.352</td><td align="center" valign="top" rowspan="1" colspan="1">0.500&#x02013;3.659</td><td align="center" valign="top" rowspan="1" colspan="1">0.552</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP</td><td align="center" valign="top" rowspan="1" colspan="1">3.483</td><td align="center" valign="top" rowspan="1" colspan="1">1.417&#x02013;8.563</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.007</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.588</td><td align="center" valign="top" rowspan="1" colspan="1">0.831&#x02013;8.060</td><td align="center" valign="top" rowspan="1" colspan="1">0.101</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APAHCE II score</td><td align="center" valign="top" rowspan="1" colspan="1">2.370</td><td align="center" valign="top" rowspan="1" colspan="1">1.048&#x02013;5.358</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.038</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">4.010</td><td align="center" valign="top" rowspan="1" colspan="1">1.334&#x02013;12.056</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.013</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SOFA score</td><td align="center" valign="top" rowspan="1" colspan="1">5.571</td><td align="center" valign="top" rowspan="1" colspan="1">1.672&#x02013;18.583</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.005</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.960</td><td align="center" valign="top" rowspan="1" colspan="1">1.062&#x02013;14.762</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.040</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HOXA&#x02010;AS2</td><td align="center" valign="top" rowspan="1" colspan="1">2.587</td><td align="center" valign="top" rowspan="1" colspan="1">1.146&#x02013;5.841</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.022</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">5.380</td><td align="center" valign="top" rowspan="1" colspan="1">1.499&#x02013;19.308</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.010</bold>
</td></tr></tbody></table><table-wrap-foot id="crj70082-ntgp-0005"><fn id="crj70082-note-0005"><p>Abbreviations: APACHE, acute physiology and chronic health evaluation; BMI, body mass index; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CRP, C&#x02010;reactive protein; Scr, serum creatinine; SOFA, sequential organ failure assessment; WBC, white blood cells.</p></fn></table-wrap-foot></table-wrap></sec><sec id="crj70082-sec-0022"><label>3.6</label><title>Overexpression of HOXA&#x02010;AS2 Alleviates LPS&#x02010;Induced Damage to HPMECs</title><p>LPS can inhibit cell growth, and cell viability decreases as treatment time extends (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, Figure&#x000a0;<xref rid="crj70082-fig-0004" ref-type="fig">4A</xref>). This validates the successful construction of the ARDS cell model in&#x000a0;vitro. In&#x000a0;vitro, LPS significantly decreased the level of HOXA&#x02010;AS2 (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, Figure&#x000a0;<xref rid="crj70082-fig-0004" ref-type="fig">4B</xref>). However, this downregulation is usually reversed by overexpressing HOXA&#x02010;AS2 (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, Figure&#x000a0;<xref rid="crj70082-fig-0004" ref-type="fig">4C</xref>). As shown in Figure&#x000a0;<xref rid="crj70082-fig-0004" ref-type="fig">4</xref>, LPS can inhibit the proliferation of HPMECs, promote apoptosis, and increase the level of inflammatory factors (IL&#x02010;6, TNF&#x02010;&#x003b1;, IL&#x02010;1&#x003b2;, and IL&#x02010;8). However, overexpression of HOXA&#x02010;AS2 can reverse these results (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, Figure&#x000a0;<xref rid="crj70082-fig-0004" ref-type="fig">4D&#x02013;F</xref>). We also measured the levels of Syndecan&#x02010;1 and MMP9 under different conditions, LPS decreased and increased the levels of Syndecan&#x02010;1 and MMP9, respectively. After upregulating HOXA&#x02010;AS2, we observed the opposite result (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, Figure&#x000a0;<xref rid="crj70082-fig-0004" ref-type="fig">4G</xref>).</p><fig position="float" fig-type="FIGURE" id="crj70082-fig-0004"><label>FIGURE 4</label><caption><p>HOXA&#x02010;AS2 restrained LPS&#x02010;induced damage to human pulmonary microvascular endothelial cells (HPMECs). (A) Cell viability of HPMECs after LPS treatment. CCK&#x02010;8 method was used to determine cell viability. (B) The level of HOXA&#x02010;AS2 after LPS treatment. The level of HOXA&#x02010;AS2 was determined by RT&#x02010;qPCR. (C) The effect of transfection with overexpression plasmids on HOXA&#x02010;AS2. (D) CCK&#x02010;8 method was used to determine cell viability. (E) Apoptosis kits and flow cytometry were used to measure apoptosis rate. (F) The levels of inflammatory factors were measured by ELISA assay. (G) the mRNA levels of syndecan&#x02010;1 and MMP9 were measured by the RT&#x02010;qPCR. ***<italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. Control; ###<italic toggle="no">p</italic>&#x02009;&#x0003c;&#x02009;0.001 vs. LPS&#x02009;+&#x02009;oe&#x02010;NC.</p></caption><graphic xlink:href="CRJ-19-e70082-g005" position="anchor" id="jats-graphic-9"/></fig></sec></sec><sec sec-type="discussion" id="crj70082-sec-0023"><label>4</label><title>Discussion</title><p>Sepsis is a life&#x02010;threatening organ dysfunction caused by a dysfunctional response to infection [<xref rid="crj70082-bib-0025" ref-type="bibr">25</xref>]. Despite the availability of effective antibiotics and established life&#x02010;supporting treatments, sepsis continues to have a high mortality rate [<xref rid="crj70082-bib-0026" ref-type="bibr">26</xref>]. ARDS is a diffuse lung injury and acute respiratory failure due to various causes, characterized by damage to alveolar epithelial cells and pulmonary capillary endothelial cells [<xref rid="crj70082-bib-0027" ref-type="bibr">27</xref>]. Research indicates that sepsis associated ARDS has a higher disease severity and mortality rate than non&#x02010;sepsis associated ARDS [<xref rid="crj70082-bib-0028" ref-type="bibr">28</xref>]. Sepsis&#x02010;associated ARDS accounts for about 30% of sepsis patients, and the fatality rate reaches 30%&#x02013;40% [<xref rid="crj70082-bib-0029" ref-type="bibr">29</xref>]. Sepsis associated ARDS is a heterogeneous clinical syndrome with a complex pathogenesis, and our ability to predict its development and prognosis is still limited. Biomarkers can help identify sepsis patients at an early stage, predict the risk of ARDS, and stratify patients at risk and reveal prognosis. While there are still no targeted drug treatments for ARDS, biomarkers can help deepen our understanding of the pathophysiology and identify potential new therapeutic targets and strategies.</p><p>In our study, we found that the level of HOXA&#x02010;AS2 was significantly reduced in sepsis patients compared to non&#x02010;sepsis patients. This finding aligns with Huifeng Wu's study [<xref rid="crj70082-bib-0017" ref-type="bibr">17</xref>], which also reported decreased levels of HOXA&#x02010;AS2 in sepsis patients. Moreover, our study found that HOXA&#x02010;AS2 is not only a diagnostic biomarker for sepsis but also can predicts the onset of ARDS in sepsis patients. Levels of HOXA&#x02010;AS2 are lower in sepsis patients who develop ARDS compared to those who do not. Our multivariate logistic regression analysis further indicates that HOXA&#x02010;AS2 is an independent risk factor for ARDS in sepsis patients. Research has shown that the occurrence of ARDS triggers macrophages to release pro&#x02010;inflammatory cytokines [<xref rid="crj70082-bib-0030" ref-type="bibr">30</xref>]. This surge in pro&#x02010;inflammatory cytokines causes damage to alveolar epithelial cells and capillary endothelium [<xref rid="crj70082-bib-0031" ref-type="bibr">31</xref>]. HOXA&#x02010;AS2 has been shown to play an inhibitory role in endothelial cell inflammation [<xref rid="crj70082-bib-0020" ref-type="bibr">20</xref>, <xref rid="crj70082-bib-0032" ref-type="bibr">32</xref>]. Therefore, decreased HOXA&#x02010;AS2 levels could be a significant cause of ARDS in sepsis patients. HOXA&#x02010;AS2 cannot only serve as a diagnostic marker for patients with sepsis but also act as a risk factor to indicate the risk of ARDS.</p><p>Prognosis plays a crucial role in medicine as it helps predict the course and outcome of a disease. Evaluating prognosis assists doctors in devising a treatment plan to better manage disease progression and improve patients' quality of life. Therefore, we also evaluated the relationship between HOXA&#x02010;AS2 levels and the prognosis of sepsis patients. After a 28&#x02010;day follow up, we found that HOXA&#x02010;AS2 levels were significantly lower in patients who died. This led us to hypothesize that a decreased HOXA&#x02010;AS2 level correlates with a higher mortality rate in sepsis patients. To further validate our hypothesis, we analyzed the correlation between HOXA&#x02010;AS2 levels and SOFA score and APACHE II score. The SOFA score and APACHE II score are commonly used to assess the severity of sepsis and to predict the prognosis of sepsis patients. Higher scores indicate more severe organ damage and a worse prognosis. Our findings showed that HOXA&#x02010;AS2 levels negatively correlated with both SOFA and APACHE II scores, suggesting that lower HOXA&#x02010;AS2 levels are associated with more severe sepsis. A multivariate logistic regression analysis further confirmed that a reduced HOXA&#x02010;AS2 level is an independent risk factor for death in sepsis patients. Therefore, our results indicate that the level of HOXA&#x02010;AS2 is closely related to the mortality rate of patients with sepsis. Clinically, it may be possible to assist in screening patients with a high risk of death by detecting the level of HOXA&#x02010;AS2.</p><p>To further explore the mechanism of HOXA&#x02010;AS2 involved in the development of ARDS, we constructed a sepsis&#x02010;associated ARDS cell model by treating HPMEC cells with LPS. LPS is a component of the outer membrane of Gram&#x02010;negative bacteria that can trigger dysregulated host responses and inflammation in sepsis and ARDS [<xref rid="crj70082-bib-0033" ref-type="bibr">33</xref>]. In our study, LPS reduced the cell viability of HPMEC, accelerated apoptosis, and encouraged the secretion of pro&#x02010;inflammatory factors such as IL&#x02010;6, TNF&#x02010;&#x003b1;, IL&#x02010;1&#x003b2;, and IL&#x02010;8. These effects were reversed by overexpressing HOXA&#x02010;AS2, suggesting that HOXA&#x02010;AS2 inhibits the progression of sepsis&#x02010;induced ARDS by suppressing the inflammatory response. Increased endothelial permeability is another major characteristic of ARDS. Studies have demonstrated that elevated vascular endothelial permeability can cause pulmonary edema, eventually leading to respiratory failure. The degradation of the endothelial glycocalyx, a layer of polyglycoprotein complexes that cover endothelial cells with an average thickness of 0.1&#x02013;2&#x02009;um, is a significant factor in increasing vascular endothelial permeability [<xref rid="crj70082-bib-0034" ref-type="bibr">34</xref>]. Degradation of the endothelial glycocalyx was found to occur in sepsis and sepsis&#x02010;induced ARDS [<xref rid="crj70082-bib-0035" ref-type="bibr">35</xref>]. The endothelial glycocalyx is associated with vascular homeostasis and organ dysfunction in sepsis [<xref rid="crj70082-bib-0036" ref-type="bibr">36</xref>]. Syndecan&#x02010;1 is a core protein comprising the endothelial glycocalyx, and it is an important structural component of the endothelial glycocalyx [<xref rid="crj70082-bib-0037" ref-type="bibr">37</xref>]. MMP&#x02010;9, which can directly degrade Syndecan&#x02010;1, is closely associated with the degradation of the endothelial glycocalyx [<xref rid="crj70082-bib-0038" ref-type="bibr">38</xref>]. In our study, in addition to its role in inflammatory events in ARDS, we found that HOXA&#x02010;AS2 is associated with endothelial glycocalyx degradation. Overexpression of HOXA&#x02010;AS2 increased Syndecan&#x02010;1 levels and decreased MMP&#x02010;9 levels, alleviating LPS&#x02010;induced endothelial glycocalyx degradation. Therefore, our results suggest that the decrease in HOXA&#x02010;AS2 levels may accelerate the occurrence and progression of ARDS by promoting inflammation and glycocalyx degradation in HPMEC cells.</p><p>To sum up, our research confirmed that HOXA&#x02010;AS2 cannot only serve as a diagnostic marker for patients with sepsis but also predict the risk of ARDS and death in patients with sepsis. The decreased level of HOXA&#x02010;AS2 increases the probability of ARDS and death in patients with sepsis. HOXA&#x02010;AS2 may partially delay the occurrence and development of ARDS by inhibiting the inflammation of pulmonary microvascular endothelial cells and the degradation of glycocalyx.</p></sec><sec id="crj70082-sec-0025"><title>Ethics Statement</title><p>The study protocol was approved by The Ethics Committee of Wuxi Branch of Zhongda Hospital Southeast University and followed the principles outlined in the Declaration of Helsinki.</p></sec><sec sec-type="conclusions" id="crj70082-sec-0026"><title>Consent</title><p>In addition, informed consent has been obtained from the participants involved.</p></sec><sec sec-type="COI-statement" id="crj70082-sec-0027"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ack id="crj70082-sec-0024"><title>Acknowledgments</title><p>The authors have nothing to report.</p></ack><sec sec-type="data-availability" id="crj70082-sec-0029"><title>Data Availability Statement</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></sec><ref-list content-type="cited-references" id="crj70082-bibl-0001"><title>References</title><ref id="crj70082-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="crj70082-cit-0001">
<string-name>
<given-names>A.</given-names>
<surname>Mirijello</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Tosoni</surname>
</string-name>, and On Behalf of <collab collab-type="authors">the Internal Medicine Sepsis Study G</collab>
, &#x0201c;<article-title>New Strategies for Treatment of Sepsis</article-title>,&#x0201d; <source>Medicina (Kaunas, Lithuania)</source>
<volume>56</volume>, no. <issue>10</issue> (<year>2020</year>): <elocation-id>527</elocation-id>, <pub-id pub-id-type="doi">10.3390/medicina56100527</pub-id>.<pub-id pub-id-type="pmid">33050538</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="crj70082-cit-0002">
<string-name>
<given-names>W.</given-names>
<surname>Wang</surname>
</string-name> and <string-name>
<given-names>C. F.</given-names>
<surname>Liu</surname>
</string-name>, &#x0201c;<article-title>Sepsis Heterogeneity</article-title>,&#x0201d; <source>World Journal of Pediatrics: WJP</source>
<volume>19</volume>, no. <issue>10</issue> (<year>2023</year>): <fpage>919</fpage>&#x02013;<lpage>927</lpage>.<pub-id pub-id-type="pmid">36735197</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="crj70082-cit-0003">
<string-name>
<given-names>I.</given-names>
<surname>Srzic</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Nesek Adam</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Tunjic Pejak</surname>
</string-name>, &#x0201c;<article-title>Sepsis Definition: What's New in the Treatment Guidelines</article-title>,&#x0201d; <source>Acta Clinica Croatica</source>
<volume>61</volume>, no. <issue>Suppl 1</issue> (<year>2022</year>): <fpage>67</fpage>&#x02013;<lpage>72</lpage>.</mixed-citation></ref><ref id="crj70082-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="crj70082-cit-0004">
<string-name>
<given-names>L. D.</given-names>
<surname>Hudson</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Milberg</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Anardi</surname>
</string-name>, and <string-name>
<given-names>R. J.</given-names>
<surname>Maunder</surname>
</string-name>, &#x0201c;<article-title>Clinical Risks for Development of the Acute Respiratory Distress Syndrome</article-title>,&#x0201d; <source>American Journal of Respiratory and Critical Care Medicine</source>
<volume>151</volume>, no. <issue>2 Pt 1</issue> (<year>1995</year>): <fpage>293</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">7842182</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="crj70082-cit-0005">
<string-name>
<given-names>P. E.</given-names>
<surname>Pepe</surname>
</string-name>, <string-name>
<given-names>R. T.</given-names>
<surname>Potkin</surname>
</string-name>, <string-name>
<given-names>D. H.</given-names>
<surname>Reus</surname>
</string-name>, <string-name>
<given-names>L. D.</given-names>
<surname>Hudson</surname>
</string-name>, and <string-name>
<given-names>C. J.</given-names>
<surname>Carrico</surname>
</string-name>, &#x0201c;<article-title>Clinical Predictors of the Adult Respiratory Distress Syndrome</article-title>,&#x0201d; <source>American Journal of Surgery</source>
<volume>144</volume>, no. <issue>1</issue> (<year>1982</year>): <fpage>124</fpage>&#x02013;<lpage>130</lpage>.<pub-id pub-id-type="pmid">7091520</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="crj70082-cit-0006">
<string-name>
<given-names>S.</given-names>
<surname>Kaku</surname>
</string-name>, <string-name>
<given-names>C. D.</given-names>
<surname>Nguyen</surname>
</string-name>, <string-name>
<given-names>N. N.</given-names>
<surname>Htet</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Acute Respiratory Distress Syndrome: Etiology, Pathogenesis, and Summary on Management</article-title>,&#x0201d; <source>Journal of Intensive Care Medicine</source>
<volume>35</volume>, no. <issue>8</issue> (<year>2020</year>): <fpage>723</fpage>&#x02013;<lpage>737</lpage>.<pub-id pub-id-type="pmid">31208266</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="crj70082-cit-0007">
<string-name>
<given-names>R. D.</given-names>
<surname>Stapleton</surname>
</string-name>, <string-name>
<given-names>B. M.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>L. D.</given-names>
<surname>Hudson</surname>
</string-name>, <string-name>
<given-names>G. D.</given-names>
<surname>Rubenfeld</surname>
</string-name>, <string-name>
<given-names>E. S.</given-names>
<surname>Caldwell</surname>
</string-name>, and <string-name>
<given-names>K. P.</given-names>
<surname>Steinberg</surname>
</string-name>, &#x0201c;<article-title>Causes and Timing of Death in Patients With ARDS</article-title>,&#x0201d; <source>Chest</source>
<volume>128</volume>, no. <issue>2</issue> (<year>2005</year>): <fpage>525</fpage>&#x02013;<lpage>532</lpage>.<pub-id pub-id-type="pmid">16100134</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="crj70082-cit-0008">
<string-name>
<given-names>G. D.</given-names>
<surname>Rubenfeld</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Caldwell</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Peabody</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Incidence and Outcomes of Acute Lung Injury</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>353</volume>, no. <issue>16</issue> (<year>2005</year>): <fpage>1685</fpage>&#x02013;<lpage>1693</lpage>.<pub-id pub-id-type="pmid">16236739</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="crj70082-cit-0009">
<string-name>
<given-names>S. E.</given-names>
<surname>Erickson</surname>
</string-name>, <string-name>
<given-names>G. S.</given-names>
<surname>Martin</surname>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Davis</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Matthay</surname>
</string-name>, <string-name>
<given-names>M. D.</given-names>
<surname>Eisner</surname>
</string-name>, and <collab collab-type="authors">Network NNA</collab>
, &#x0201c;<article-title>Recent Trends in Acute Lung Injury Mortality: 1996&#x02010;2005</article-title>,&#x0201d; <source>Critical Care Medicine</source>
<volume>37</volume>, no. <issue>5</issue> (<year>2009</year>): <fpage>1574</fpage>&#x02013;<lpage>1579</lpage>, <pub-id pub-id-type="doi">10.1097/CCM.0b013e31819fefdf</pub-id>.<pub-id pub-id-type="pmid">19325464</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="crj70082-cit-0010">
<string-name>
<given-names>M. C.</given-names>
<surname>Bridges</surname>
</string-name>, <string-name>
<given-names>A. C.</given-names>
<surname>Daulagala</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Kourtidis</surname>
</string-name>, &#x0201c;<article-title>LNCcation: lncRNA Localization and Function</article-title>,&#x0201d; <source>Journal of Cell Biology</source>
<volume>220</volume>, no. <issue>2</issue> (<year>2021</year>): <elocation-id>e202009045</elocation-id>.<pub-id pub-id-type="pmid">33464299</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="crj70082-cit-0011">
<string-name>
<given-names>F.</given-names>
<surname>Di Gesualdo</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Capaccioli</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Lulli</surname>
</string-name>, &#x0201c;<article-title>A Pathophysiological View of the Long Non&#x02010;Coding RNA World</article-title>,&#x0201d; <source>Oncotarget</source>
<volume>5</volume>, no. <issue>22</issue> (<year>2014</year>): <fpage>10976</fpage>&#x02013;<lpage>10996</lpage>.<pub-id pub-id-type="pmid">25428918</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="crj70082-cit-0012">
<string-name>
<given-names>O.</given-names>
<surname>Wapinski</surname>
</string-name> and <string-name>
<given-names>H. Y.</given-names>
<surname>Chang</surname>
</string-name>, &#x0201c;<article-title>Long Noncoding RNAs and Human Disease</article-title>,&#x0201d; <source>Trends in Cell Biology</source>
<volume>21</volume>, no. <issue>6</issue> (<year>2011</year>): <fpage>354</fpage>&#x02013;<lpage>361</lpage>.<pub-id pub-id-type="pmid">21550244</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="crj70082-cit-0013">
<string-name>
<given-names>M.</given-names>
<surname>Kato</surname>
</string-name>, &#x0201c;<article-title>Noncoding RNAs as Therapeutic Targets in Early Stage Diabetic Kidney Disease</article-title>,&#x0201d; <source>Kidney Research and Clinical Practice</source>
<volume>37</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>197</fpage>&#x02013;<lpage>209</lpage>.<pub-id pub-id-type="pmid">30254844</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="crj70082-cit-0014">
<string-name>
<given-names>X.</given-names>
<surname>Lv</surname>
</string-name>, <string-name>
<given-names>X. Y.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Zhang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>lncRNA NEAT1 Aggravates Sepsis&#x02010;Induced Lung Injury by Regulating the miR&#x02010;27a/PTEN Axis</article-title>,&#x0201d; <source>Laboratory Investigation</source>
<volume>101</volume>, no. <issue>10</issue> (<year>2021</year>): <fpage>1371</fpage>&#x02013;<lpage>1381</lpage>.<pub-id pub-id-type="pmid">34239033</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="crj70082-cit-0015">
<string-name>
<given-names>X.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Chen</surname>
</string-name>, and <string-name>
<given-names>L.</given-names>
<surname>Yu</surname>
</string-name>, &#x0201c;<article-title>The Value of Circulating Long Non&#x02010;Coding RNA Maternally Expressed Gene 3 as a Predictor of Higher Acute Respiratory Distress Syndrome Risk and 28&#x02010;Day Mortality in Sepsis Patients</article-title>,&#x0201d; <source>Journal of Clinical Laboratory Analysis</source>
<volume>34</volume>, no. <issue>11</issue> (<year>2020</year>): <elocation-id>e23488</elocation-id>.<pub-id pub-id-type="pmid">32844492</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="crj70082-cit-0016">
<string-name>
<given-names>S.</given-names>
<surname>Xiao</surname>
</string-name> and <string-name>
<given-names>B.</given-names>
<surname>Song</surname>
</string-name>, &#x0201c;<article-title>LncRNA HOXA&#x02010;AS2 Promotes the Progression of Prostate Cancer via Targeting miR&#x02010;509&#x02010;3p/PBX3 Axis</article-title>,&#x0201d; <source>Bioscience Reports</source>
<volume>40</volume>, no. <issue>8</issue> (<year>2020</year>): <elocation-id>BSR20193289</elocation-id>.</mixed-citation></ref><ref id="crj70082-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="crj70082-cit-0017">
<string-name>
<given-names>H.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name>
<given-names>Z.</given-names>
<surname>Ma</surname>
</string-name>, &#x0201c;<article-title>Long Noncoding RNA HOXA&#x02010;AS2 Mediates MicroRNA&#x02010;106b&#x02010;5p to Repress Sepsis&#x02010;Engendered Acute Kidney Injury</article-title>,&#x0201d; <source>Journal of Biochemical and Molecular Toxicology</source>
<volume>34</volume>, no. <issue>4</issue> (<year>2020</year>): <elocation-id>e22453</elocation-id>.<pub-id pub-id-type="pmid">32048402</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="crj70082-cit-0018">
<string-name>
<given-names>K.</given-names>
<surname>Gao</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Lv</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Yue</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Xu</surname>
</string-name>, &#x0201c;<article-title>Long Noncoding RNA HOXA&#x02010;AS2 Ameliorates Chronic Intermittent Hypoxia&#x02010;Induced Lung Inflammation by Regulating miR&#x02010;17&#x02010;5p/tipe2 Axis</article-title>,&#x0201d; <source>Allergol Immunopathol (Madr)</source>
<volume>51</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>36</fpage>&#x02013;<lpage>44</lpage>.</mixed-citation></ref><ref id="crj70082-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="crj70082-cit-0019">
<string-name>
<given-names>A. Y.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>Y. Y.</given-names>
<surname>Zhao</surname>
</string-name>, <string-name>
<given-names>Z. J.</given-names>
<surname>Zhou</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Microarray Analysis of Long Non&#x02010;Coding RNAs in Lung Tissues of Patients With COPD and HOXA&#x02010;AS2 Promotes HPMECs Proliferation via Notch1</article-title>,&#x0201d; <source>International Journal of Chronic Obstructive Pulmonary Disease</source>
<volume>15</volume> (<year>2020</year>): <fpage>2449</fpage>&#x02013;<lpage>2460</lpage>.<pub-id pub-id-type="pmid">33116460</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="crj70082-cit-0020">
<string-name>
<given-names>X.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Yu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>LncRNA HOXA&#x02010;AS2 Represses Endothelium Inflammation by Regulating the Activity of NF&#x02010;&#x003ba;B Signaling</article-title>,&#x0201d; <source>Atherosclerosis</source>
<volume>281</volume> (<year>2019</year>): <fpage>38</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">30658190</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="crj70082-cit-0021">
<string-name>
<given-names>C.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Du</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Vagal Efferent Fiber Stimulation Ameliorates Pulmonary Microvascular Endothelial Cell Injury by Downregulating Inflammatory Responses</article-title>,&#x0201d; <source>Inflammation</source>
<volume>36</volume>, no. <issue>6</issue> (<year>2013</year>): <fpage>1567</fpage>&#x02013;<lpage>1575</lpage>.<pub-id pub-id-type="pmid">23912647</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="crj70082-cit-0022">
<string-name>
<given-names>Y.</given-names>
<surname>Deng</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Hu</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Deficiency of Endothelial FGFR1 Signaling via Upregulation of ROCK2 Activity Aggravated ALI/ARDS</article-title>,&#x0201d; <source>Frontiers in Immunology</source>
<volume>14</volume> (<year>2023</year>): <elocation-id>1041533</elocation-id>.<pub-id pub-id-type="pmid">36969192</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="crj70082-cit-0023">
<string-name>
<given-names>A.</given-names>
<surname>Rhodes</surname>
</string-name>, <string-name>
<given-names>L. E.</given-names>
<surname>Evans</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Alhazzani</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016</article-title>,&#x0201d; <source>Intensive Care Medicine</source>
<volume>43</volume>, no. <issue>3</issue> (<year>2017</year>): <fpage>304</fpage>&#x02013;<lpage>377</lpage>.<pub-id pub-id-type="pmid">28101605</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="crj70082-cit-0024">
<string-name>
<given-names>A. D. T.</given-names>
<surname>Force</surname>
</string-name>, <string-name>
<given-names>V. M.</given-names>
<surname>Ranieri</surname>
</string-name>, <string-name>
<given-names>G. D.</given-names>
<surname>Rubenfeld</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Acute Respiratory Distress Syndrome: The Berlin Definition</article-title>,&#x0201d; <source>Journal of the American Medical Association</source>
<volume>307</volume>, no. <issue>23</issue> (<year>2012</year>): <fpage>2526</fpage>&#x02013;<lpage>2533</lpage>.<pub-id pub-id-type="pmid">22797452</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="crj70082-cit-0025">
<string-name>
<given-names>L.</given-names>
<surname>Evans</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Rhodes</surname>
</string-name>, <string-name>
<given-names>W.</given-names>
<surname>Alhazzani</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021</article-title>,&#x0201d; <source>Critical Care Medicine</source>
<volume>49</volume>, no. <issue>11</issue> (<year>2021</year>): <fpage>1974</fpage>&#x02013;<lpage>1982</lpage>.<pub-id pub-id-type="pmid">34643578</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="crj70082-cit-0026">
<string-name>
<given-names>H.</given-names>
<surname>Ogura</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Gando</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Saitoh</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Epidemiology of Severe Sepsis in Japanese Intensive Care Units: A Prospective Multicenter Study</article-title>,&#x0201d; <source>Journal of Infection and Chemotherapy</source>
<volume>20</volume>, no. <issue>3</issue> (<year>2014</year>): <fpage>157</fpage>&#x02013;<lpage>162</lpage>.<pub-id pub-id-type="pmid">24530102</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="crj70082-cit-0027">
<string-name>
<given-names>N. J.</given-names>
<surname>Meyer</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Gattinoni</surname>
</string-name>, and <string-name>
<given-names>C. S.</given-names>
<surname>Calfee</surname>
</string-name>, &#x0201c;<article-title>Acute Respiratory Distress Syndrome</article-title>,&#x0201d; <source>Lancet</source>
<volume>398</volume>, no. <issue>10300</issue> (<year>2021</year>): <fpage>622</fpage>&#x02013;<lpage>637</lpage>.<pub-id pub-id-type="pmid">34217425</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="crj70082-cit-0028">
<string-name>
<given-names>X.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Xu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Pei</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Association Between Oxygenation Status at 24 h After Diagnosis of Pulmonary Acute Respiratory Distress Syndrome and the 30&#x02010;Day Mortality Among Pediatric Oncological Patients</article-title>,&#x0201d; <source>Frontiers in Pediatrics</source>
<volume>10</volume> (<year>2022</year>): <elocation-id>805264</elocation-id>.<pub-id pub-id-type="pmid">35633973</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="crj70082-cit-0029">
<string-name>
<given-names>H.</given-names>
<surname>Gong</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Chen</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Advanced Development and Mechanism of Sepsis&#x02010;Related Acute Respiratory Distress Syndrome</article-title>,&#x0201d; <source>Frontiers in Medicine (Lausanne)</source>
<volume>9</volume> (<year>2022</year>): <elocation-id>1043859</elocation-id>.</mixed-citation></ref><ref id="crj70082-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="crj70082-cit-0030">
<string-name>
<given-names>H.</given-names>
<surname>Banavasi</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Nguyen</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Osman</surname>
</string-name>, and <string-name>
<given-names>A. O.</given-names>
<surname>Soubani</surname>
</string-name>, &#x0201c;<article-title>Management of ARDS&#x02014;What Works and What Does Not</article-title>,&#x0201d; <source>American Journal of the Medical Sciences</source>
<volume>362</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>13</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">34090669</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="crj70082-cit-0031">
<string-name>
<given-names>G.</given-names>
<surname>Bellani</surname>
</string-name>, <string-name>
<given-names>J. G.</given-names>
<surname>Laffey</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Pham</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries</article-title>,&#x0201d; <source>Journal of the American Medical Association</source>
<volume>315</volume>, no. <issue>8</issue> (<year>2016</year>): <fpage>788</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="pmid">26903337</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="crj70082-cit-0032">
<string-name>
<given-names>X.</given-names>
<surname>Li</surname>
</string-name> and <string-name>
<given-names>H. M.</given-names>
<surname>Yu</surname>
</string-name>, &#x0201c;<article-title>Overexpression of HOXA&#x02010;AS2 Inhibits Inflammation and Apoptosis in Podocytes via Sponging miRNA&#x02010;302b&#x02010;3p to Upregulate TIMP3</article-title>,&#x0201d; <source>European Review for Medical and Pharmacological Sciences</source>
<volume>24</volume>, no. <issue>9</issue> (<year>2020</year>): <fpage>4963</fpage>&#x02013;<lpage>4970</lpage>.<pub-id pub-id-type="pmid">32432759</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="crj70082-cit-0033">
<string-name>
<given-names>D.</given-names>
<surname>Brooks</surname>
</string-name>, <string-name>
<given-names>L. C.</given-names>
<surname>Barr</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Wiscombe</surname>
</string-name>, <string-name>
<given-names>D. F.</given-names>
<surname>McAuley</surname>
</string-name>, <string-name>
<given-names>A. J.</given-names>
<surname>Simpson</surname>
</string-name>, and <string-name>
<given-names>A. J.</given-names>
<surname>Rostron</surname>
</string-name>, &#x0201c;<article-title>Human Lipopolysaccharide Models Provide Mechanistic and Therapeutic Insights Into Systemic and Pulmonary Inflammation</article-title>,&#x0201d; <source>European Respiratory Journal</source>
<volume>56</volume>, no. <issue>1</issue> (<year>2020</year>): <elocation-id>1901298</elocation-id>, <pub-id pub-id-type="doi">10.1183/13993003.01298-2019</pub-id>.<pub-id pub-id-type="pmid">32299854</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="crj70082-cit-0034">
<string-name>
<given-names>L.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Ma</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Berberine Alleviates Endothelial Glycocalyx Degradation and Promotes Glycocalyx Restoration in LPS&#x02010;Induced ARDS</article-title>,&#x0201d; <source>International Immunopharmacology</source>
<volume>65</volume> (<year>2018</year>): <fpage>96</fpage>&#x02013;<lpage>107</lpage>.<pub-id pub-id-type="pmid">30308440</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="crj70082-cit-0035">
<string-name>
<given-names>R. C.</given-names>
<surname>Sullivan</surname>
</string-name>, <string-name>
<given-names>M. D.</given-names>
<surname>Rockstrom</surname>
</string-name>, <string-name>
<given-names>E. P.</given-names>
<surname>Schmidt</surname>
</string-name>, and <string-name>
<given-names>J. A.</given-names>
<surname>Hippensteel</surname>
</string-name>, &#x0201c;<article-title>Endothelial Glycocalyx Degradation During Sepsis: Causes and Consequences</article-title>,&#x0201d; <source>Matrix Biology Plus</source>
<volume>12</volume> (<year>2021</year>): <elocation-id>100094</elocation-id>.<pub-id pub-id-type="pmid">34917925</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="crj70082-cit-0036">
<string-name>
<given-names>A. N.</given-names>
<surname>Rizzo</surname>
</string-name> and <string-name>
<given-names>E. P.</given-names>
<surname>Schmidt</surname>
</string-name>, &#x0201c;<article-title>The Role of the Alveolar Epithelial Glycocalyx in Acute Respiratory Distress Syndrome</article-title>,&#x0201d; <source>American Journal of Physiology. Cell Physiology</source>
<volume>324</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>C799</fpage>&#x02013;<lpage>C806</lpage>.<pub-id pub-id-type="pmid">36847444</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="crj70082-cit-0037">
<string-name>
<given-names>K.</given-names>
<surname>Suzuki</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Okada</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Sumi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Serum Syndecan&#x02010;1 Reflects Organ Dysfunction in Critically Ill Patients</article-title>,&#x0201d; <source>Scientific Reports</source>
<volume>11</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>8864</fpage>.<pub-id pub-id-type="pmid">33893369</pub-id>
</mixed-citation></ref><ref id="crj70082-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="crj70082-cit-0038">
<string-name>
<given-names>A. W.</given-names>
<surname>Mulivor</surname>
</string-name> and <string-name>
<given-names>H. H.</given-names>
<surname>Lipowsky</surname>
</string-name>, &#x0201c;<article-title>Inhibition of Glycan Shedding and Leukocyte&#x02010;Endothelial Adhesion in Postcapillary Venules by Suppression of Matrixmetalloprotease Activity With Doxycycline</article-title>,&#x0201d; <source>Microcirculation</source>
<volume>16</volume>, no. <issue>8</issue> (<year>2009</year>): <fpage>657</fpage>&#x02013;<lpage>666</lpage>.<pub-id pub-id-type="pmid">19905966</pub-id>
</mixed-citation></ref></ref-list></back></article>